Notwithstanding positive clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant opposition from managed care entities. Such insurers are frequently creating obstacles to access, like steep price requirements and approval processes that restrict user availability. Analysts b